Pirtobrutinib | Interleukin Related interleukin-related.com

Product Name :
Pirtobrutinib

Search keywords :
Pirtobrutinib

drugId :
null

Target Vo:
Tyrosine-protein kinase BTK

Target Vo Short Name :
BTK

Moa_Name:
Tyrosine-protein kinase BTK inhibitors

First Approval Country :
United States

First Approval Date Filter:
2023

Origin Company_Name :
Redx Pharma Ltd

Active Company_Name :
Bend Research Inc

Active Indication_Name:
Leukemia, Lymphocytic, Chronic, B-Cell

In Active Indication_Name:
Multiple Sclerosis

Termination Status :

China Termination Status :

Highest Status:
Approved

China Highest Status:
NDA/BLA

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Pertuzumab Biological Activity
Anetumab Purity
Bcl-XL Antibody: Bcl-XL Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 26 kDa, targeting to Bcl-XL. It can be used for WB,ICC/IF,IHC-P,FC,IP assays with tag free, in the background of Human.

Author: Interleukin Related

Related Posts